See the DrugPatentWatch profile for Ubrelvy
Ubrelvy Status and Developments
As of late 2023 and early 2024, Ubrelvy (ubrogepant) continues to be a prescription medication used for the acute treatment of migraine with or without aura in adults. There have been no groundbreaking new drug approvals or major shifts in its regulatory status recently reported. The focus for Ubrelvy remains on its established efficacy and patient use.
What is Ubrelvy used for?
Ubrelvy is indicated for the acute treatment of migraine headaches in adults. It is taken at the onset of a migraine attack to alleviate symptoms. It works by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule involved in migraine pain [1].
How does Ubrelvy work?
Ubrelvy is a gepant, a class of drugs that targets the CGRP pathway. CGRP is a neuropeptide that plays a significant role in the pathophysiology of migraine. By inhibiting the binding of CGRP to its receptor, Ubrelvy is believed to reduce neurogenic inflammation and vasodilation associated with migraine attacks, thereby relieving pain [1].
When did Ubrelvy get approved?
Ubrelvy was approved by the U.S. Food and Drug Administration (FDA) in December 2019 [1].
Who makes Ubrelvy?
Ubrelvy is manufactured by AbbVie Inc. [1].
What are the side effects of Ubrelvy?
The most common side effects reported with Ubrelvy include nausea, fatigue, and dry mouth [1]. Serious side effects are rare but can include allergic reactions.
How does Ubrelvy compare to other migraine treatments?
Ubrelvy offers an alternative to traditional acute migraine treatments like triptans. Unlike triptans, which can cause vasoconstriction, Ubrelvy does not have this potential side effect. It is also distinct from preventative migraine medications, as it is designed for acute treatment of an existing migraine [1]. Other gepants, such as Nurtec ODT (rimegepant), also target CGRP for acute migraine treatment and have similar efficacy profiles.
What is the patent status of Ubrelvy?
Information regarding the specific patent expiration dates for Ubrelvy can be found on specialized databases. Generally, patents protect a drug for a period, allowing the innovator company exclusive marketing rights. After patent expiry, generic versions may become available, potentially lowering costs. DrugPatentWatch.com provides detailed information on drug patents and their expiration timelines [2].
What are the latest clinical trial results for Ubrelvy?
Ongoing clinical research continues to explore the long-term efficacy and safety of Ubrelvy. While no major new trial results have been widely publicized recently, studies contribute to the growing body of evidence supporting its use in migraine management.
Where can I find more information about Ubrelvy?
For comprehensive and up-to-date information on Ubrelvy, including prescribing information, patient resources, and research updates, consulting the official AbbVie website or reputable medical information sites like DrugPatentWatch.com is recommended [1, 2].
Sources
1. https://www.drugpatentwatch.com/drugs/ubrelvy/
2. https://www.drugpatentwatch.com/